Affordable Cystic Fibrosis (CF) Transmembrane Conductance Regulator Modulator Drugs for CF: All CF Lives Worldwide Matter!
作者信息
Zampoli Marco, Verstraete Janine, Baird Cathy, Calligaro Greg, Morrow Brenda
机构信息
Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, South Africa.
Adult Cystic Fibrosis Clinic, Netcare Milpark Hospital, Johannesburg, South Africa; and.
出版信息
Am J Respir Crit Care Med. 2023 Nov 1;208(9):915-916. doi: 10.1164/rccm.202307-1200VP.
Abstract
摘要
相似文献
1
Affordable Cystic Fibrosis (CF) Transmembrane Conductance Regulator Modulator Drugs for CF: All CF Lives Worldwide Matter!用于囊性纤维化（CF）的价格亲民的囊性纤维化跨膜传导调节因子调节剂药物：全球所有囊性纤维化患者的生命都至关重要！
Am J Respir Crit Care Med. 2023 Nov 1;208(9):915-916. doi: 10.1164/rccm.202307-1200VP.
2
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.囊性纤维化跨膜电导调节因子 (CFTR) 调节剂对囊性纤维化巨噬细胞功能有不同的影响。
Sci Rep. 2018 Nov 20;8(1):17066. doi: 10.1038/s41598-018-35151-7.
3
Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.炎性细胞因子 TNF-α 和 IL-17 增强囊性纤维化跨膜电导调节剂调节剂的疗效。
J Clin Invest. 2021 Aug 16;131(16). doi: 10.1172/JCI150398.
4
One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.一概而论：囊性纤维化因果治疗的过去、现在和未来。
Cells. 2022 Jun 8;11(12):1868. doi: 10.3390/cells11121868.
5
Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.囊性纤维化跨膜转导调节因子增效剂作为有前途的囊性纤维化治疗方法。
Expert Opin Investig Drugs. 2011 Mar;20(3):423-5. doi: 10.1517/13543784.2011.554823. Epub 2011 Feb 9.
6
The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.高效囊性纤维化跨膜电导调节剂调节剂对女性囊性纤维化患者健康的影响。
Clin Ther. 2023 Mar;45(3):278-289. doi: 10.1016/j.clinthera.2023.01.016. Epub 2023 Feb 24.
7
A Proteomic Survey of the Cystic Fibrosis Transmembrane Conductance Regulator Surfaceome.囊性纤维化跨膜电导调节蛋白表面蛋白组学研究。
Int J Mol Sci. 2023 Jul 14;24(14):11457. doi: 10.3390/ijms241411457.
8
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.囊性纤维化跨膜电导调节因子调节剂在囊性纤维化中的肺外作用。
Ann Am Thorac Soc. 2020 Feb;17(2):147-154. doi: 10.1513/AnnalsATS.201909-671CME.
9
Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.囊性纤维化跨膜电导调节剂调节剂治疗：耳鼻喉科医生的综述。
Am J Rhinol Allergy. 2020 Jul;34(4):573-580. doi: 10.1177/1945892420912368. Epub 2020 Mar 13.
10
Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.囊性纤维化个体化医学：从调节剂开发到治疗罕见 CFTR 突变的囊性纤维化患者。
Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L529-L543. doi: 10.1152/ajplung.00465.2017. Epub 2017 Dec 14.
引用本文的文献
1
Building Lay Society Knowledge and Education for Health Technology Assessment and Policy Engagement: Case of CFTR Modulator Access in Brazil.构建面向卫生技术评估与政策参与的公众社会知识与教育：以巴西CFTR调节剂的可及性为例
Healthcare (Basel). 2025 Aug 14;13(16):1996. doi: 10.3390/healthcare13161996.
2
The globalization of cystic fibrosis care.囊性纤维化护理的全球化。
Curr Opin Pediatr. 2025 Jun 1;37(3):266-271. doi: 10.1097/MOP.0000000000001458. Epub 2025 Mar 27.
3
Social determinants of respiratory health from birth: still of concern in the 21st century?从出生起就存在影响呼吸健康的社会决定因素：在 21 世纪仍然令人担忧？
Eur Respir Rev. 2024 Apr 10;33(172). doi: 10.1183/16000617.0222-2023. Print 2024 Apr 30.
4
Phoenix from the Ashes: Celebrating the 2023 North American Cystic Fibrosis Conference.浴火重生：庆祝2023年北美囊性纤维化会议
Am J Respir Crit Care Med. 2023 Nov 1;208(9):909-910. doi: 10.1164/rccm.202309-1603ED.
本文引用的文献
1
Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!囊性纤维化跨膜传导调节因子调节剂药物可及性方面的现实世界差异与伦理考量：关注差距！
Front Pharmacol. 2023 Mar 27;14:1163391. doi: 10.3389/fphar.2023.1163391. eCollection 2023.
2
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.依列卡福妥/替扎卡福妥/依伐卡托在囊性纤维化患者中的真实世界安全性和有效性：一项基于长期注册研究的中期结果
J Cyst Fibros. 2023 Jul;22(4):730-737. doi: 10.1016/j.jcf.2023.03.002. Epub 2023 Mar 22.
3
How many billions is enough? Prioritizing profits over patients with cystic fibrosis.多少亿才算够？将利润置于囊性纤维化患者之上。
Pediatr Pulmonol. 2023 May;58(5):1595-1597. doi: 10.1002/ppul.26335. Epub 2023 Feb 10.
4
Accelerating pooled licensing of medicines to enhance global production and equitable access.加快药品集中许可以提高全球产量并促进公平获取。
Lancet. 2022 Aug 20;400(10352):632-634. doi: 10.1016/S0140-6736(22)01013-3. Epub 2022 Jul 8.
5
An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.囊性纤维化中新型疗法 CFTR 调节剂的研究进展。
Paediatr Drugs. 2022 Jul;24(4):321-333. doi: 10.1007/s40272-022-00509-y. Epub 2022 May 16.
6
Current prices versus minimum costs of production for CFTR modulators.当前价格与 CFTR 调节剂的最低生产成本。
J Cyst Fibros. 2022 Sep;21(5):866-872. doi: 10.1016/j.jcf.2022.04.007. Epub 2022 Apr 16.
Zotero 插件